Mode
Text Size
Log in / Sign up
N/A N=39 Randomized Triple-blind Treatment

Effect of Cocoa Supplementation Peripheral and Autonomic Diabetic Neuropathy

Diabetic Neuropathies

Enrolled (actual)
39
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Toronto Clinical Scoring System (TCSS) — -2.63; -1.84; 9.31; 6.89 Score on a scale — p=>0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cocoa (Dietary_supplement); Placebo (Other)
Age
Adult · 40+ yrs
Sex
All
Sponsor
Anahuac University
Primary completion
Jun 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Toronto Clinical Scoring System (TCSS)
-2.63; -1.84; 9.31; 6.89; 6.68; 5.05 >0.05
SECONDARY
Rate-dependent Depression of the H-reflex
0.13; 0.01; 0.87; 0.88; 0.99; 0.89 >0.05
SECONDARY
BEST Questionnaire
-1.45; -2.21; 9.35; 9.05; 7.9; 6.84 >0.05
SECONDARY
Bristol Stool Form Scale
40; 57.8; 30; 52.6 >0.05
SECONDARY
Weight
0.38; -0.42; 73.5; 82.8; 74.4; 82.5 >0.05
SECONDARY
Waist Circumference
-0.8; -1.38; 96.7; 103; 96.5; 103 >0.05
SECONDARY
Waist-to-Height Ratio
-0.00; -0.00; 0.6; 0.64; 0.6; 0.64 >0.05
SECONDARY
Abdominal Circumference
-0.75; -1.02; 100; 106; 100; 105 >0.05
SECONDARY
Systolic Blood Pressure
-3.7; -3.78; 126; 127; 125; 130 >0.05
SECONDARY
Diastolic Blood Pressure
-2.32; -2.36; 79.9; 78.1; 78.7; 79 >0.05
SECONDARY
Glucose
-17; -38.1; 169; 195; 152; 157 >0.05
SECONDARY
Glycated Hemoglobin A1c
-0.17; -0.27; 7.82; 8.28; 7.72; 8 >0.05
SECONDARY
Triglycerides
-4.96; -13.9; 182; 179; 177; 165 >0.05
SECONDARY
High-density Lipoprotein Cholesterol
-0.86; 2.18; 37.8; 38.2; 36.9; 40.4 >0.05
SECONDARY
Triglycerides/HDL Ratio
-0.02; -0.74; 5.12; 4.99; 5.1; 4.25 >0.05
SECONDARY
Low-density Lipoprotein Cholesterol
8.88; 4.15; 112; 108; 121; 112 >0.05
SECONDARY
Neutrophil/Lymphocyte Ratio
-0.09; 0.15; 1.96; 1.76; 1.87; 1.92 >0.05
SECONDARY
Diabetes 39 Instrument
-9.19; -5.26; 43.4; 35.6; 34.2; 30.4 >0.05

Summary

Type 2 diabetes mellitus is a high incidence disease in Mexico and is associated with the development of chronic degenerative complications such as diabetic neuropathy. The latter manifests itself as a set of disorders that occur as a consequence of a chronic hyperglycemic state that can induce oxidative stress and inflammation, resulting in damage to the autonomic and peripheral nervous system. In Mexico, it has been reported that this complication usually occurs between 29% and 90% of patients with diabetes. Cocoa is a food with a high content of flavonoids, which are phenolic compounds with antioxidant and anti-inflammatory effects. Additionally, its consumption has been associated with a decrease in hyperglycemia and insulin resistance, improvement in mitochondrial function, and, based on the above, an effect on diabetic complications has been suggested; This has been demonstrated in in vivo and in vitro models, but not in the human population. Once the symptoms of diabetic neuropathy have started, palliative treatments are prescribed, and to date there are no pharmacological compounds that have been shown to reverse the consequences of diabetic peripheral and autonomic neuropathy. Additionally, clinical trials of compounds with antioxidant properties have only performed subjective evaluations based on questionnaires on the perception of the improvement of diabetic neuropathy and some biochemical markers or nerve conduction tests, however, the results shown have not been conclusive. This is why a double-blind, randomized controlled clinical trial is proposed, with the objective of evaluating the effect of cocoa supplementation in patients with type 2 diabetes mellitus and peripheral and autonomic diabetic neuropathy on a) the biochemical profile, which includes the evaluation of the glycemic and lipid profile, quantification of pro-inflammatory cytokines and oxidative stress markers; b) the clinical profile through the application of standardized questionnaires, anthropometric measurements and blood pressure, and c) somatosensory processing through the paired pulse H reflex test. The hypothesis of this study is that cocoa supplementation will have a beneficial effect on the biochemical and clinical profile and somatosensory processing of peripheral and autonomic diabetic neuropathy.

Eligibility Criteria

Inclusion Criteria

  • Adults aged 40-60 years with a diagnosis of type 2 diabetes mellitus and diabetic neuropathy
  • Minimum time of diagnosis of T2DM of 5 years
  • Who have a Michigan Neuropathy Screening Instrument (MNSI) score ≥2
  • Male and Female
  • Have them sign the informed consent letter

Exclusion Criteria

  • Subjects who modify their pharmacological treatment during the study
  • Subjects who do not attend one of the intermediate consultations
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05247034). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search